|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
13
|
|
pubmed:dateCreated |
2004-6-30
|
|
pubmed:abstractText |
Promising new therapeutic options for follicular lymphoma (FL) include fludarabine plus mitoxantrone (FM) and the mouse/human anti-CD20 antibody, rituximab. We performed a randomized comparative trial of FM with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) front-line chemotherapy with and without sequential rituximab.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:AlinariLapoL,
pubmed-author:BaccaraniMicheleM,
pubmed-author:CicconeFabrizioF,
pubmed-author:De RenzoAmaliaA,
pubmed-author:FaliniBrunangeloB,
pubmed-author:FattoriPier PaoloPP,
pubmed-author:GentiliniPatriziaP,
pubmed-author:GobbiMarcoM,
pubmed-author:GuardigniLucianoL,
pubmed-author:LautaVito MicheleVM,
pubmed-author:MartelliMaurizioM,
pubmed-author:MolinariAnna LiaAL,
pubmed-author:PerrottiAlessioA,
pubmed-author:PileriStefanoS,
pubmed-author:PulsoniAlessandroA,
pubmed-author:SoveriniSimonaS,
pubmed-author:StortiSergioS,
pubmed-author:TucciAlessandraA,
pubmed-author:TuraSanteS,
pubmed-author:ZajaFrancescoF,
pubmed-author:ZinzaniPier LuigiPL
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2654-61
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:15159414-Administration, Oral,
pubmed-meshheading:15159414-Adult,
pubmed-meshheading:15159414-Aged,
pubmed-meshheading:15159414-Antibodies, Monoclonal,
pubmed-meshheading:15159414-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:15159414-Antineoplastic Agents,
pubmed-meshheading:15159414-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15159414-Cyclophosphamide,
pubmed-meshheading:15159414-Disease-Free Survival,
pubmed-meshheading:15159414-Doxorubicin,
pubmed-meshheading:15159414-Drug Administration Schedule,
pubmed-meshheading:15159414-Female,
pubmed-meshheading:15159414-Humans,
pubmed-meshheading:15159414-Infusions, Intravenous,
pubmed-meshheading:15159414-Lymphoma, Follicular,
pubmed-meshheading:15159414-Male,
pubmed-meshheading:15159414-Middle Aged,
pubmed-meshheading:15159414-Prednisone,
pubmed-meshheading:15159414-Treatment Outcome,
pubmed-meshheading:15159414-Vincristine
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
|
|
pubmed:affiliation |
Institute of Hematology and Medical Oncology L. e A. Seràgnoli, University of Bologna, Italy. plzinzo@med.unibo.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
